Stocklytics Platform
Asset logo for symbol ANVS
Annovis Bio
ANVS37
$1.71arrow_drop_up5.45%$0.09
Penny Stock
Asset logo for symbol ANVS
ANVS37

$1.71

arrow_drop_up5.45%
Key Stats
Open$1.69
Prev. Close$1.65
EPS-4.22
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$33.32M
PE Ratio-
LOWHIGH
Day Range1.61
1.75
52 Week Range1.53
22.49
Ratios
Revenue-
EBITDA Margin %-
EPS-4.22
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.92%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ANVS-
US Healthcare Sector-
US Market-
check_circle

ANVS / Market

ANVS exceeded the US Market which returned 2.09% over the last twenty four hours.
check_circle

ANVS / Healthcare Sector

ANVS exceeded the US Healthcare sector which returned 3.60% over the last twenty four hours.

Annovis Bio (ANVS) Statistics

Annovis Bio Inc (ANVS) is a biopharmaceutical company focused on developing novel therapeutics for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead product candidate, ANVS401, is a small molecule drug designed to target and inhibit the toxic proteins amyloid beta and tau, which are believed to play a key role in the development and progression of these diseases. By targeting these proteins, ANVS401 has the potential to slow or halt the neurodegenerative process and preserve cognitive function in affected individuals.
In terms of valuation metrics, Annovis Bio Inc currently has a market capitalization of $X. The company's stock price has experienced significant volatility in recent months, reflecting the speculative nature of biopharmaceutical investments. However, ANVS has shown strong performance relative to its sector, outperforming the average sector return by X% over the past year. This performance can be attributed to the promising clinical data generated by ANVS401, which has demonstrated positive effects on cognitive function in preclinical and early-stage clinical trials.
add Annovis Bio  to watchlist

Keep an eye on Annovis Bio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Annovis Bio (ANVS) stock's performance compared to its sector and the market over the past year?

Over the past year, Annovis Bio (ANVS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 21.28%, Annovis Bio has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.40%, it has fallen short of the market average. This comparison highlights Annovis Bio 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Annovis Bio (ANVS) stock?

The PE ratio for Annovis Bio (ANVS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Annovis Bio (ANVS) stock?

The Earnings Per Share (EPS) for Annovis Bio (ANVS), calculated on a diluted basis, is -$4.22. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Annovis Bio (ANVS) stock?

The operating margin for Annovis Bio (ANVS) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Annovis Bio (ANVS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Annovis Bio (ANVS) is $0. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Annovis Bio (ANVS) have?

Annovis Bio (ANVS) has a total debt of $0. The net debt, which accounts for cash and cash equivalents against the total debt, is -$12.64M.

Take Your Investments to a Whole New Level